Sonidegib

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Sonidegib

CAS No. : 956697-53-3

MCE 国际站：Sonidegib

产品活性：Sonidegib (Erismodegib) 是一种有效，选择性的 Smo 拮抗剂，抑制鼠和人Smo的IC₅₀ 分别为 1.3 nM 和 2.5 nM。

研究领域：Stem Cell/Wnt

作用靶点：Smo

In Vitro: The IC₅₀ values for Sonidegib (NVP-LDE225) for the major human CYP450 drug metabolizing enzymes is greater than 10 μM. Sonidegib (LDE225), a small molecule, clinically investigated SMO inhibitor, used alone and in combination with Nilotinib, inhibits the Hh pathway in CD34⁺ chronic phase (CP)-chronic myeloid leukaemia (CML) cells, reducing the number and self-renewal capacity of CML leukaemia stem cell (LSC). Sonidegib interacts directly with SMO, in a similar fashion to cyclopamine, to reduce expression of downstream Hh signaling targets. Primary CD34⁺ CP-CML cells are cultured in serum free media (SFM)±Sonidegib for 6, 24 and 72 hours (h). At 72 h, while there is variability between the biological samples, GLI1 is significantly downregulated following exposure to Sonidegib (10 nM; 0.78-fold and 100 nM; 0.73-fold, respectively (p<0.01).

In Vivo: Sonidegib (NVP-LDE225) is a weak base with a measured pK_a of 4.2 and exhibits relatively poor aqueous solubility. In the subcutaneous Ptch^+/-p53^-/- medulloblastoma allograft mouse model, Sonidegib demonstrates dose-related antitumor activity after 10 days of oral administration of a suspension of the diphosphate salt. At a dose of 5 mg/kg/day qd, Sonidegib significantly inhibits tumor growth, corresponding to a T/C value of 33% (p<0.05 as compared to vehicle controls). When dosed at 10 and 20 mg/kg/day qd, Sonidegib affords 51 and 83% regression, respectively. Bone marrow cells and spleen cells from a subset of treated mice are transplanted into secondary recipient mice. Transplantation of either bone marrow (BM) or spleen cells from mice treated with Sonidegib (LDE225)+Nilotinib results in reduced white cell count (WCC) and reduces leukaemia development in secondary recipients compared to Sonidegib or Nilotinib alone.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Stem Cell Signaling Compound Library  |  Wnt/Hedgehog/Notch Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Targeted Therapy Drug Library   |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  FDA-Approved Anticancer Drug Library  |  Anti-Prostate Cancer Compound Library  |  Cancer Stem Cells Compound Library  |  Highly Selective Inhibitors Library  |  SAG  |  Cyclopamine  |  Purmorphamine  |  SANT-1  |  Glasdegib  |  DY131  |  20(S)-Hydroxycholesterol  |  Sonidegib diphosphate  |  BMS-833923  |  Taladegib  |  KAAD-Cyclopamine  |  Halcinonide  |  PF-5274857  |  Jervine  |  Saridegib  |  GSA-10  |  Saikosaponin B1  |  ALLO-2  |  CUR61414  |  HhAntag  |  LEQ506  |  MK-4101  |  MRT-81  |  MRT-83  |  AZD7254  |  AZD8542

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds